Global MMR Vaccine Market By Age Group (Infants and Preschooler), By End User (Hospitals, Clinics, and Healthcare Centers) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa)
Market Outlook:
The global MMR vaccine market was valued at USD 697.4 Million in 2019 and is projected to reach USD 938.9 Million by 2027, expanding at a CAGR of 3.8% during the forecast period. Measles, mumps, and rubella (MMR) vaccines are a fusion of live viruses that are given as an injection. Live viruses are inactivated and cannot replicate in the human cells as immune system develops a response and defends against the infection.
Market Dynamics
The market is driven by factors such as rising incidences of MMR, increasing number of patients with autoimmune disease, growing focus on immunization programs, and increasing awareness among consumers for vaccine. Conversely, high cost of vaccine development and lack of information and unavailability of vaccines in rural areas are key restraints of this market. Growth of healthcare providers in emerging markets an opportunity for vaccine manufacturer, rise in adoption of MMR Vaccine to prevent corona virus infectious disease (COVID-19), and increase in adoption of combination vaccines are boosting the market.
Segmental Outlook
On the basis of age group, the global MMR vaccine market is bifurcated into infants and preschooler. The infant segment is anticipated to expand at a CAGR of 3.7% during the forecast period due to rising government initiatives to decrease the prevalence of diseases through immunization. The preschooler segment is estimated to hold 41.0% share of the market in 2020 owing to its increasing effectiveness in immunity from the measles, mumps, and rubella.
Based on end-users, the market is segmented into hospitals, clinics, and healthcare centers. The hospital segment is projected to hold a major share of the market during the forecast period owing to the increasing incorporation of the MMR vaccine in a majority of private and public hospitals globally. The healthcare centers segment is expected to grow at a substantial pace due to improvements in infrastructure and universal healthcare systems, especially in developing countries.
Definitions
By Age Group
Infant: An infant is term used for the newborn baby or neonatal, and toddler. The infant age ranges from 12 months to 18 months are generally given the first dose of the MMR vaccine. In certain circumstances, infants can receive MMR vaccine from the age of 6 months, for example for post exposure prophylaxis Intramuscular IG (IGIM) condition. The vaccine is rarely repeated again, if the 1st dose is given at < 11 months of age. The repeat dose of MMR vaccine is not always required and is subjected to certain special cases of children. The immunization status of the infant or neonatal is determined in order to give the MMR vaccine to the baby before completing the 12months of the age. A dose provided at about 11 months of age (before 12 months of age) can provide sufficient immunogenic, particularly in infants born to mothers with vaccinated antibody measles rather than natural infection. One dose of MMR vaccine is 93% effective against measles, 78% effective against mumps, and 97% effective against rubella.
Pre-schooler: Children aged between 4 years to 6 years are termed preschoolers. Children in this age group are not considered as infants. Most of the children in this age attend formal nursery programs. In formal nursery programs, the preschoolers usually learn basic life skills, independence, and basic skills require when they proceed with primary schooling. The 2nd dose of the MMR vaccine is usually advised to be given in this period of age to children to fully prevent the body from measles, mumps, and rubella virus for a lifetime. Two doses of MMR vaccine are 97% effective against measles and 88% effective against mumps.
Infant: An infant is term used for the newborn baby or neonatal, and toddler. The infant age ranges from 12 months to 18 months are generally given the first dose of the MMR vaccine. In certain circumstances, infants can receive MMR vaccine from the age of 6 months, for example for post exposure prophylaxis Intramuscular IG (IGIM) condition. The vaccine is rarely repeated again, if the 1st dose is given at < 11 months of age. The repeat dose of MMR vaccine is not always required and is subjected to certain special cases of children. The immunization status of the infant or neonatal is determined in order to give the MMR vaccine to the baby before completing the 12months of the age. A dose provided at about 11 months of age (before 12 months of age) can provide sufficient immunogenic, particularly in infants born to mothers with vaccinated antibody measles rather than natural infection. One dose of MMR vaccine is 93% effective against measles, 78% effective against mumps, and 97% effective against rubella.
Pre-schooler: Children aged between 4 years to 6 years are termed preschoolers. Children in this age group are not considered as infants. Most of the children in this age attend formal nursery programs. In formal nursery programs, the preschoolers usually learn basic life skills, independence, and basic skills require when they proceed with primary schooling. The 2nd dose of the MMR vaccine is usually advised to be given in this period of age to children to fully prevent the body from measles, mumps, and rubella virus for a lifetime. Two doses of MMR vaccine are 97% effective against measles and 88% effective against mumps.
By End User
Hospital: A hospital is a health care facility that provides patients with specialist medical and nursing services, and medical facilities. Hospitals are categorized as general, specialty, or government, depending on the source of income earned. A general hospital is the most well-known type of hospital. It usually has an emergency ward to cater to urgent health problems ranging from burn and accident victims to a sudden illness. A district hospital is a healthcare facility having multiple beds for intensive care and additional beds for patients in need of long-term care. Hospitals have a number of departments (including surgery and emergency care) and specialist facilities including cardiology. Some hospitals have divisions for outpatients and others have facilities for chronic treatments. Specific units of support include pharmacy, pathology, and radiology.
Clinic: A clinic (or medical clinic or hospital clinic) is a health-care facility mainly for the treatment of the outpatient. Clinics can be run privately or controlled and financed publicly. Clinics cover the primary healthcare needs of the population in local communities by providing specialized treatments and admitting patients for overnight stays. Clinics are associated with a general practice of medicine run by one or more general practitioners. Healthcare provided in India, China, Russia, and counties in Africa through mobile health clinics or roadside dispensaries.
Healthcare center: A healthcare center, health center, or community health center is a network of clinics staffed by a group of general practitioners and nurses providing health care services to individuals in a given area. Typical services covered include family practice and dental care; however, some healthcare centers have grown considerably and include internal medicine, pediatrics, women's care, family planning, pharmacy, optometry, and laboratory testing. In countries with facilities of universal healthcare systems, most people prefer treatment from the healthcare centers. Large healthcare centers in Central and Eastern Europe are commonly called policlinics.
Regional Outlook
In terms of regions, the market is fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is a promising region for the market. The region constituted 50.0% share of the market in 2020. The market in the region is projected to expand at a CAGR of 4.2% during the forecast period. Increasing population and rising healthcare expenditure are driving the MMR vaccine market in Asia Pacific. The market in North America is projected to expand at a CAGR of 3.6% due growing prevalence of measles in the region.
Competitive Landscape
- Key players in the market include GlaxoSmithKline plc., Merck & Co., Inc., Serum Institute of India Pvt. Ltd. These companies are considered manufacturers of MMR Vaccine based on their revenue, research development (R&D) activities, regional presence, and supply chain management system.
- The players are adopting key strategies such as acquisition, and geographical expansion where potential opportunity for the MMR Vaccine extraction is added in the company’s capacity.
- For instance, in 2020, Merck & Co., Inc. completed the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer.
- In May 2020, GlaxoSmithKline plc. and Samsung Biologics Co. Ltd., a contract development, manufacturing, and analytical testing services company, entered into partnership for providing additional capacity of manufacturing and supplying of innovative biopharmaceutical therapies to former.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global MMR Vaccine Market
- Historical, Current and Projected Market Size in terms of Value
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global MMR Vaccine Market Performance
Segments
Key Segments CoveredBy Age Group
- Infants
- Preschooler
- Hospitals
- Clinics
- Healthcare Centers
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Europe
- U.K.
- France
- Germany
- Italy
- Spain
- Poland
- Rest of the Europe
- Asia Pacific
- India
- China
- Pakistan
- Indonesia
- Bangladesh
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Nigeria
- DR of Congo
- Ethiopia
- Rest of Middle East & Africa
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Serum Institute of India Pvt. Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 MMR Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 MMR Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 MMR Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the MMR Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global MMR Vaccine Market Size & Forecast, 2017-2027
4.5.1 MMR Vaccine Market Size and Y-o-Y Growth
4.5.2 MMR Vaccine Market Absolute $ Opportunity
4.6 Global MMR Vaccine Market: Impact Of Key Regulations
Chapter 5 Global MMR Vaccine Market Analysis and Forecast By Age Group
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Age Group
5.1.2 Basis Point Share (BPS) Analysis By Age Group
5.1.3 Absolute $ Opportunity Assessment By Age Group
5.2 MMR Vaccine Market Size Forecast By Age Group
5.2.1 Infants
5.2.2 Preschooler
5.3 Market Attractiveness Analysis By Age Group
Chapter 6 Global MMR Vaccine Market Analysis and Forecast By End-User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By End-User
6.1.2 Basis Point Share (BPS) Analysis By End-User
6.1.3 Absolute $ Opportunity Assessment By End-User
6.2 MMR Vaccine Market Size Forecast By End-User
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Healthcare
6.3 Market Attractiveness Analysis By End-User
Chapter 7 Global MMR Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 MMR Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America MMR Vaccine Analysis and Forecast
9.1 Introduction
9.2 North America MMR Vaccine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America MMR Vaccine Market Size Forecast By Age Group
9.6.1 Infants
9.6.2 Preschooler
9.7 Basis Point Share (BPS) Analysis By Age Group
9.8 Absolute $ Opportunity Assessment By Age Group
9.9 Market Attractiveness Analysis By Age Group
9.10 North America MMR Vaccine Market Size Forecast By End-User
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Healthcare
9.11 Basis Point Share (BPS) Analysis By End-User
9.12 Absolute $ Opportunity Assessment By End-User
9.13 Market Attractiveness Analysis By End-User
Chapter 10 Europe MMR Vaccine Analysis and Forecast
10.1 Introduction
10.2 Europe MMR Vaccine Market Size Forecast by Country
10.2.1 U.K.
10.2.2 France
10.2.3 Germany
10.2.4 Italy
10.2.5 Spain
10.2.6 Poland
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe MMR Vaccine Market Size Forecast By Age Group
10.6.1 Infants
10.6.2 Preschooler
10.7 Basis Point Share (BPS) Analysis By Age Group
10.8 Absolute $ Opportunity Assessment By Age Group
10.9 Market Attractiveness Analysis By Age Group
10.10 Europe MMR Vaccine Market Size Forecast By End-User
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Healthcare
10.11 Basis Point Share (BPS) Analysis By End-User
10.12 Absolute $ Opportunity Assessment By End-User
10.13 Market Attractiveness Analysis By End-User
Chapter 11 Asia Pacific MMR Vaccine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific MMR Vaccine Market Size Forecast by Country
11.2.1 India
11.2.2 China
11.2.3 Pakistan
11.2.4 Indonesia
11.2.5 Bangladesh
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific MMR Vaccine Market Size Forecast By Age Group
11.6.1 Infants
11.6.2 Preschooler
11.7 Basis Point Share (BPS) Analysis By Age Group
11.8 Absolute $ Opportunity Assessment By Age Group
11.9 Market Attractiveness Analysis By Age Group
11.10 Asia Pacific MMR Vaccine Market Size Forecast By End-User
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Healthcare
11.11 Basis Point Share (BPS) Analysis By End-User
11.12 Absolute $ Opportunity Assessment By End-User
11.13 Market Attractiveness Analysis By End-User
Chapter 12 Latin America MMR Vaccine Analysis and Forecast
12.1 Introduction
12.2 Latin America MMR Vaccine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America MMR Vaccine Market Size Forecast By Age Group
12.6.1 Infants
12.6.2 Preschooler
12.7 Basis Point Share (BPS) Analysis By Age Group
12.8 Absolute $ Opportunity Assessment By Age Group
12.9 Market Attractiveness Analysis By Age Group
12.10 Latin America MMR Vaccine Market Size Forecast By End-User
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Healthcare
12.11 Basis Point Share (BPS) Analysis By End-User
12.12 Absolute $ Opportunity Assessment By End-User
12.13 Market Attractiveness Analysis By End-User
Chapter 13 Middle East & Africa (MEA) MMR Vaccine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) MMR Vaccine Market Size Forecast by Country
13.2.1 Nigeria
13.2.2 DR of Congo
13.2.3 Ethiopia
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) MMR Vaccine Market Size Forecast By Age Group
13.6.1 Infants
13.6.2 Preschooler
13.7 Basis Point Share (BPS) Analysis By Age Group
13.8 Absolute $ Opportunity Assessment By Age Group
13.9 Market Attractiveness Analysis By Age Group
13.10 Middle East & Africa (MEA) MMR Vaccine Market Size Forecast By End-User
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Healthcare
13.11 Basis Point Share (BPS) Analysis By End-User
13.12 Absolute $ Opportunity Assessment By End-User
13.13 Market Attractiveness Analysis By End-User
Chapter 14 Competition Landscape
14.1 MMR Vaccine Market: Competitive Dashboard
14.2 Global MMR Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline plc.
14.3.2 Merck & Co., Inc.
14.3.3 Serum Institute of India Pvt. Ltd.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 MMR Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 MMR Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 MMR Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the MMR Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global MMR Vaccine Market Size & Forecast, 2017-2027
4.5.1 MMR Vaccine Market Size and Y-o-Y Growth
4.5.2 MMR Vaccine Market Absolute $ Opportunity
4.6 Global MMR Vaccine Market: Impact Of Key Regulations
Chapter 5 Global MMR Vaccine Market Analysis and Forecast By Age Group
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Age Group
5.1.2 Basis Point Share (BPS) Analysis By Age Group
5.1.3 Absolute $ Opportunity Assessment By Age Group
5.2 MMR Vaccine Market Size Forecast By Age Group
5.2.1 Infants
5.2.2 Preschooler
5.3 Market Attractiveness Analysis By Age Group
Chapter 6 Global MMR Vaccine Market Analysis and Forecast By End-User
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By End-User
6.1.2 Basis Point Share (BPS) Analysis By End-User
6.1.3 Absolute $ Opportunity Assessment By End-User
6.2 MMR Vaccine Market Size Forecast By End-User
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Healthcare
6.3 Market Attractiveness Analysis By End-User
Chapter 7 Global MMR Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 MMR Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America MMR Vaccine Analysis and Forecast
9.1 Introduction
9.2 North America MMR Vaccine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America MMR Vaccine Market Size Forecast By Age Group
9.6.1 Infants
9.6.2 Preschooler
9.7 Basis Point Share (BPS) Analysis By Age Group
9.8 Absolute $ Opportunity Assessment By Age Group
9.9 Market Attractiveness Analysis By Age Group
9.10 North America MMR Vaccine Market Size Forecast By End-User
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Healthcare
9.11 Basis Point Share (BPS) Analysis By End-User
9.12 Absolute $ Opportunity Assessment By End-User
9.13 Market Attractiveness Analysis By End-User
Chapter 10 Europe MMR Vaccine Analysis and Forecast
10.1 Introduction
10.2 Europe MMR Vaccine Market Size Forecast by Country
10.2.1 U.K.
10.2.2 France
10.2.3 Germany
10.2.4 Italy
10.2.5 Spain
10.2.6 Poland
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe MMR Vaccine Market Size Forecast By Age Group
10.6.1 Infants
10.6.2 Preschooler
10.7 Basis Point Share (BPS) Analysis By Age Group
10.8 Absolute $ Opportunity Assessment By Age Group
10.9 Market Attractiveness Analysis By Age Group
10.10 Europe MMR Vaccine Market Size Forecast By End-User
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Healthcare
10.11 Basis Point Share (BPS) Analysis By End-User
10.12 Absolute $ Opportunity Assessment By End-User
10.13 Market Attractiveness Analysis By End-User
Chapter 11 Asia Pacific MMR Vaccine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific MMR Vaccine Market Size Forecast by Country
11.2.1 India
11.2.2 China
11.2.3 Pakistan
11.2.4 Indonesia
11.2.5 Bangladesh
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific MMR Vaccine Market Size Forecast By Age Group
11.6.1 Infants
11.6.2 Preschooler
11.7 Basis Point Share (BPS) Analysis By Age Group
11.8 Absolute $ Opportunity Assessment By Age Group
11.9 Market Attractiveness Analysis By Age Group
11.10 Asia Pacific MMR Vaccine Market Size Forecast By End-User
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Healthcare
11.11 Basis Point Share (BPS) Analysis By End-User
11.12 Absolute $ Opportunity Assessment By End-User
11.13 Market Attractiveness Analysis By End-User
Chapter 12 Latin America MMR Vaccine Analysis and Forecast
12.1 Introduction
12.2 Latin America MMR Vaccine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America MMR Vaccine Market Size Forecast By Age Group
12.6.1 Infants
12.6.2 Preschooler
12.7 Basis Point Share (BPS) Analysis By Age Group
12.8 Absolute $ Opportunity Assessment By Age Group
12.9 Market Attractiveness Analysis By Age Group
12.10 Latin America MMR Vaccine Market Size Forecast By End-User
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Healthcare
12.11 Basis Point Share (BPS) Analysis By End-User
12.12 Absolute $ Opportunity Assessment By End-User
12.13 Market Attractiveness Analysis By End-User
Chapter 13 Middle East & Africa (MEA) MMR Vaccine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) MMR Vaccine Market Size Forecast by Country
13.2.1 Nigeria
13.2.2 DR of Congo
13.2.3 Ethiopia
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) MMR Vaccine Market Size Forecast By Age Group
13.6.1 Infants
13.6.2 Preschooler
13.7 Basis Point Share (BPS) Analysis By Age Group
13.8 Absolute $ Opportunity Assessment By Age Group
13.9 Market Attractiveness Analysis By Age Group
13.10 Middle East & Africa (MEA) MMR Vaccine Market Size Forecast By End-User
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Healthcare
13.11 Basis Point Share (BPS) Analysis By End-User
13.12 Absolute $ Opportunity Assessment By End-User
13.13 Market Attractiveness Analysis By End-User
Chapter 14 Competition Landscape
14.1 MMR Vaccine Market: Competitive Dashboard
14.2 Global MMR Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline plc.
14.3.2 Merck & Co., Inc.
14.3.3 Serum Institute of India Pvt. Ltd.
Key Segments Covered
By Age Group
By Age Group
- Infants
- Preschooler
- Hospitals
- Clinics
- Healthcare Centers
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Europe
- U.K.
- France
- Germany
- Italy
- Spain
- Poland
- Rest of the Europe
- Asia Pacific
- India
- China
- Pakistan
- Indonesia
- Bangladesh
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Nigeria
- DR of Congo
- Ethiopia
- Rest of Middle East & Africa
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Serum Institute of India Pvt. Ltd.
Our Clients
FAQ Section
Some frequently asked quetions about this report!
Additional company profiles can be provided on request
Yes, the report covers product specific information such as composition development etc.
According to this Growth Market Reports report, the market from MMR Vaccine is likely to register a CAGR of 3.8% during forecast period 2020-2027, with an anticipated valuation of US$ 938.9 million by the end of the 2027.
In addition to market size (in US$ Million) and Company Market Share (in % for base year 2019), other data such as Pricing analysis for year 2017 to 2027 (estimated pricing analysis) is provided, Export Import Analysis (2015 to 2019) for Copper ores and concentrates is provided, short term and long term outlook for MMR Vaccine market is available in final report.
The Rising incidences of MMR, increasing number of patients with autoimmune disease, growing focus on immunization programs, and increasing awareness among consumers for vaccine is expected to drive the market growth during forecast period.
Hospitals and Healthcare Center are the key end-user that are driving the MMR Vaccine market.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
The market is expected to witness increment of over 3.5% between 2019 and 2020 owing to the positive impact of COVID-19 pandemic on the MMR Vaccine market. The ongoing research of MMR for COVID-19 string is expected to grow the production MMR Vaccine.
The base year considered for the global MMR Vaccine market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Major manufactures include, GlaxoSmithKline plc., Merck & Co., Inc., Serum Institute of India Pvt. Ltd.
Related Reports
Some other reports from this category!
